Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 87.5 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $71.400 million which beat the analyst consensus estimate of $60.160 million by 18.68 percent. This is a 427.87 percent increase over sales of $13.526 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。